NephrologyNow The Ultimate Guide to Kidney Disease Research

Second Chances in Mineral Metabolism

Wolf M.   Clin J Am Soc Nephrol.   2010 Jan;5(1):1-3

In this succinct editorial, Dr. Wolf reinforces the rationale for performing proper randomized controlled trials in bone mineral metabolism before changing clinical practice.  In addition, he provides insight into a first-in-class substudy of the ACHIEVE study which looks at the effects of cinacalcet and activated Vitamin D on FGF23 levels in ESRD.
Free full text kindly [...]

KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD)

These clinical practice guidelines developed by KDIGO are designed to address the diagnosis, evaluation, prevention and treatment of CKD related disorders of bone mineral metabolism.
document.getElementById(“post-1059-blankimage”).onload();

Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.

Savica V, Calò LA, Monardo P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G.   J Am Soc Nephrol.   2009 Mar;20(3):639-44

document.getElementById(“post-748-blankimage”).onload();

Salivary phosphorus binding: a novel approach to control hyperphosphatemia.

Eknoyan G.   J Am Soc Nephrol.   2009 Mar;20(3):460-2

document.getElementById(“post-749-blankimage”).onload();

Effect of Food Additives on Hyperphosphatemia Among Patients With End-stage Renal Disease A Randomized Controlled Trial.

Sullivan C, Sayre SS, Leon JB, Machekano R, Love TE, Porter D, Marbury M, Sehgal AR.   JAMA.   2009 Feb 11;301(6):629-35

document.getElementById(“post-750-blankimage”).onload();

Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.

Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van Wyck D, Kopple JD, Kalantar-Zadeh K.   J Am Soc Nephrol.   2008 Nov;19(11):2193-203

document.getElementById(“post-652-blankimage”).onload();

Oral active vitamin D is associated with improved survival in hemodialysis patients.

Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andía JB.   Kidney Int.   2008 Oct;74(8):1070-8

document.getElementById(“post-633-blankimage”).onload();

Vitamin D in chronic kidney disease: is the jury in?

de Boer IH, Kestenbaum B.   Kidney Int.   2008 Oct;74(8):985-7

document.getElementById(“post-634-blankimage”).onload();

Association of oral calcitriol with improved survival in nondialyzed CKD.

Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B.   J Am Soc Nephrol.   2008 Aug;19(8):1613-9

document.getElementById(“post-592-blankimage”).onload();

Active vitamin D and survival.

Wolf M.   J Am Soc Nephrol.   2008 Aug;19(8):1442-3

document.getElementById(“post-593-blankimage”).onload();

A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.

Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW.   Clin J Am Soc Nephrol.   2008 Jul;3(4):1131-8

document.getElementById(“post-567-blankimage”).onload();

Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease.

Coyne DW.   Nat Clin Pract Nephrol.   2008 Jul;4(7):364-5

document.getElementById(“post-580-blankimage”).onload();

Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease.

de Francisco AL, Piñera C, Palomar R.   Nat Clin Pract Nephrol.   2008 Jul;4(7):366-7

document.getElementById(“post-581-blankimage”).onload();